Recurrent oral cancer: Current and emerging therapeutic approaches

Frontiers in Pharmacology

Volumn 3 JUL, Issue , 2012, Pages

  da Silva, Sabrina Daniela ^a,b   Hier, Michael ^a   Mlynarek, Alex ^a   Kowalski, Luiz Paulo ^c   Alaoui Jamali, Moulay A ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Drug resistance; Novel therapeutics; Oral cancer; Recurrence

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PAZOPANIB; PIRARUBICIN; TOPOTECAN; TRASTUZUMAB; TRIMETREXATE; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; EPITHELIAL MESENCHYMAL TRANSITION; HEAD AND NECK CANCER; HUMAN; KIDNEY METASTASIS; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUTH CANCER; MULTIPLE MYELOMA; PANCREAS CANCER; PATIENT SELECTION; RECURRENT CANCER; RECURRENT DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84866178811     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00149     Document Type: Article

References (80)

1. Agarwal,R.,Carey,M.,Hennessy,B.,and Mills, G. B. (2010). PI3K pathwaydirected therapeutic strategies in cancer. Curr. Opin. Investig. Drugs 11, 615-628.
2. Agra, I. M., Filho, J. G., Martins, E. P., and Kowalski, L. P. (2010). Second salvage surgery for re-recurrent oral cavity and oropharynx carcinoma. Head Neck 32, 997-1002.
3. Alaoui-Jamali, M. A., Dupré, I., and Qiang,H.(2004). Prediction of drug sensitivity and drug resistance in cancer by transcriptional and pro-teomic profiling. Drug Resist. Updat. 7, 245-255.
4. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., and Schapira, M. (2012). Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400.
5. Barker, N. (2008). The canonical WNT/beta-catenin signalling pathway. Methods Mol. Biol. 468, 5-15.
6. Bennett, M., Feldmeier, J., Smee, R., and Milross, C. (2008). Hyperbaric oxygenation for tumor sensitisation to radiotherapy: a systematic review of randomised controlled trials. Cancer Treat. Rev. 34, 577-591.
7. Bernier, J., Bonner, J., Vermorken, J. B., Bensadoun, R. J., Dummer, R., Giralt, J., Kornek, G., Hartley, A., Mesia, R., Robert, C., Segaert, S., and Ang,K. K. (2008). Consensus guidelines for the management of radiation dermatitis and coexisting acnelike rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann. Oncol. 19, 142-149.
8. Bocci, G., Nicolaou, K. C., and Kerbel, R. S. (2002). Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62, 6938-6943.
9. Boyer, B., Valles, A. M., and Edme, N. (2000). Induction and regulation of epithelialmesenchymal transitions. Biochem. Pharmacol. 60, 1091-1099.
10. Braybrooke,J.P.,O'Byrne,K.J., Propper, D. J., Blann, A., Saunders, M., Dobbs, N., Han, C., Woodhull, J., Mitchell, K., Crew, J., Smith, K., Stephens, R., Ganesan, T. S., Talbot, D. C., and Harris, A. L. (2000). A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin. Cancer Res. 6, 4697-4704.
11. Browder, T., Butterfield, C. E., Kräling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res. 60, 1878-1886.
12. Califano, J., van der Riet, P., Westra, W., Nawroz, H., Clayman, G., Piantadosi, S., Corio, R., Lee, D., Green-berg, B., Koch, W., and Sidransky, D. (1996). Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 56, 2488-2492.
13. Califano, J., Westra, W. H., Meininger, G., Corio, R., Koch, W. M., and Sidransky, D. (2000). Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin. Cancer Res. 6, 347-352.
14. Carvalho, A. L., Kowalski, L. P., Agra, I. M., Pontes, E., Campos, O. D., and Pellizzon, A. C. (2005). Treatment results on advanced neck metastasis (N3) from head and neck squamous carcinoma. Otolaryngol. Head Neck Surg. 132, 862-868.
15. Chang, H. R. (2010). Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 116, 2856-2867.
16. Conacci-Sorrell, M., Zhurinsky, J., and Ben-Ze'Ev,A. (2002). The cadherincatenin adhesion system in signaling and cancer. J. Clin. Invest. 109, 987-991.
17. Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., Sugimoto, H., Rocha, R. M., Damascena, A., Brentani, R. R., and Kalluri, R. (2012). Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21, 66-82.
18. Courtney, K. D., Corcoran, R. B., and Engelman, J. A. (2010). The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075-1083.
19. Dean, M., Fojo, T., and Bates, S. (2005). Tumor stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284.
20. Debucquoy, A., Machiels, J. P., McBride, W. H., and Haustermans, K. (2010). Integrationof epidermal growth factor receptor inhibitors with preop-erative chemoradiation.Clin. Cancer Res. 16, 2709-2714.
21. Falasca, M. (2010). PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr. Pharm. Des. 16, 1410-1416.
22. Fan, S., Tang, Q. L., Lin, Y. J., Chen, W. L., Li, J. S., Huang, Z. Q., Yang, Z. H., Wang,Y. Y., Zhang, D. M., Wang, H. J., Dias-Ribeiro, E., Cai, Q., and Wang, L. (2011). A review of clinical and histological parameters associated with contralateral neck metas-tases in oral squamous cell carcinoma. Int. J. Oral Sci. 3, 180-191.
23. Folkman, J. (2007). Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286.
24. Frame,F. M., and Maitland,N.J.(2011). Cancer stem cells, models of study and implications of therapy resistance mechanisms. Adv. Exp. Med. Biol. 720, 105-118.
25. Furness, S., Glenny,A. M., Worthington, H. V., Pavitt, S., Oliver, R., Clarkson, J. E., Macluskey, M., Chan, K. K., and Conway, D. I. (2011). Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst. Rev. 4, CD006386.
26. Garraway, L. A., and Jänne, P. A. (2012). Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214-226.
27. Garzino-Demo, P., Dell'Acqua, A., Dalmasso, P., Fasolis, M., La Terra Maggiore, G. M., Ramieri, G., Berrone, S., Rampino, M., and Schena, M. (2006). Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma. J. Craniomaxillofac Surg. 34, 344-350.
28. Giaccone, G. (2000). Clinical perspectives on platinum resistance. Drugs 59, 37-38.
29. Gillet, J. P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., Padmanabhan, R., Davidson, B., Ganapathi, R., Sood, A. K., Rueda, B. R., Ambudkar, S. V., and Gottesman, M. M. (2011). Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U.S.A. 108, 18708-18713.
30. Greenberg, J. S., El-Naggar,A. K., Mo,V., Roberts, D., and Myers, J. N. (2003). Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 98, 508-515.
31. Grskovic, M., Javaherian, A., Strulovici, B., and Daley, G. Q. (2011). Induced pluripotent stem cells - opportunities for disease modelling and drug discovery. Nat. Rev. Drug Discov. 10, 915-929.
32. Hanahan, D., Bergers, G., and Bergsland, E. (2000). Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045-1047.
33. Ihle, N. T., and Powis, G. (2010). Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol. Aspects Med. 31, 135-144.
34. Jassem, J. (1999). Chemotherapy of advanced non-small cell lung cancer. Ann. Oncol. 10, 77-82.
35. Kawamoto, T., Ohga, N., Akiyama, K., Hirata, N., Kitahara, S., Maishi, N., Osawa, T., Yamamoto, K., Kondoh, M., Shindoh, M., Hida, Y., and Hida, K. (2012). Tumorderived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis. PLoS ONE 7, doi:10.1371/journal.pone.0034045
36. Kerr, D. J. (2004). Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat. Clin. Pract. Oncol. 1, 39-43.
37. Kowalski, L. P., Carvalho, A. L., Martins Priante, A. V., and Magrin, J. (2005). Predictive factors for distant metastasis from oral and oropharyngeal squamous cell carcinoma. Oral Oncol. 41, 534-541.
38. Kowalski, L. P., Magrin, J., Sabóia, M., Santos, J. C., and Torloni, H. (1998). Squamous cell carcinoma of the tongue: a review of 629 patients treated at a single institution. South Am. J. Cancer 107, 697-702.
39. Kvinlaug, B. T., and Huntly, B. J. (2007). Targeting cancer stem cells. Expert Opin. Ther. Targets 11, 915-927.
40. Lansigan, F., and Foss,F. M. (2010). Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 70, 273-286.
41. Larue, L., and Bellacosa, A. (2005). Epithelialmesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 24, 7443-7454.
42. Lebwohl, D., and Canetta, R. (1998). Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer 34, 1522-1534.
43. Leemans, C. R., Tiwari, R., Nauta, J. J., van der Waal, I., and Snow, G. B. (1994). Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 73, 187-190.
44. Lott, J. P. (2011). Vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 365, 1449-1450.
45. Ma, J., and Waxman,D. J. (2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol. Cancer Ther. 7, 3670-3684.
46. Machiels, J. P., and Schmitz, S. (2011). New advances in targeted therapies for squamous cell carcinoma of the head and neck. Anticancer Drugs 22, 626-633.
47. Mahindra, A., Laubach, J., Raje, N., Munshi, N., Richardson, P. G., and Anderson, K. (2012). Latest advances and current challenges in the treatment of multiple myeloma. Nat. Rev. Clin. Oncol. 9, 135-143.
48. Maione, F., Capano, S., Regano, D., Zentilin, L., Giacca, M., Casanovas, O., Bussolino, F., Serini, G., and Giraudo, E. (2012). Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 125, 1832-1848.
49. Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., Campbell, L. L., Polyak, K., Brisken, C., Yang, J., and Weinberg, R. A. (2008). The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
50. Mao, L., El-Naggar, A. K., Fan, Y. H., Lee, J. S., Lippman, S. M., Kayser, S., Lotan, R., and Hong, W. K. (1996). Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res. 56, 5600-5604.
51. Moreno Garcia, V., Basu, B., Molife, L. R., and Kaye, S. B. (2012). Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin. Cancer Res. 18, 3750-3761.
52. Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., and McDonald, D. M. (2002). Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985-1000.
53. Mydlarz, W. K., Hennessey, P. T., and Califano, J. A. (2010). Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opin. Med. Diagn. 4, 53-65.
54. Nawshad, A., Lagamba, D., Polad, A., and Hay,E. D. (2005). Transforming growth factorbeta signaling during epithelialmesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs (Print) 179, 11-23.
55. Nelson, W. J., and Nusse, R. (2004). Convergence of WNT, β-catenin, and cadherin pathways. Science 303, 1483-1487.
56. Okafuji, M., Ita, M., Oga, A., Hayatsu, Y., Matsuo, A., Shinzato, Y., Shinozaki, F., and Sasaki, K. (2000). The relationship of genetic aberrations detected by comparative genomic hybridization to DNA ploidy and tumor size in human oral squamous cell carcinomas. J. Oral Pathol. Med. 29, 226-231.
57. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
58. Persons, D. L., Yazlovitskaya, E. M., Cui, W., and Pelling, J. C. (1999). Cisplatininduced activation of mitogenactivated protein kinases in ovarian carcinoma cells: inhibition of extracellular signalregulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 5, 1007-1014.
59. Petersen, P. E. (2009). Oral cancer prevention and control - the approach of the World Health Organization. Oral Oncol. 45, 454-460.
60. Polyak, K., and Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273.
61. Prince, M. E., Sivanandan, R., Kaczorowski, A., Wolf, G. T., Kaplan, M. J., Dalerba, P., Weissman, I. L., Clarke,M. F., and Ailles,L. E. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. U.S.A. 104, 973-978.
62. Rapisarda, A., and Melillo, G. (2012). Overcoming disappointing results with antiangiogenic therapy by targetinghypoxia. Nat. Rev. Clin. Oncol. 9, 378-390.
63. Raza, S., Kornblum, N., Kancharla,V. P., Baig, M.A., Singh,A. B., and Kalavar, M. (2011). Emerging therapiesinthe treatment of locally advanced squamous cell cancers of head and neck. Recent Pat. Anticancer Drug. Discov. 6, 246-257.
64. Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M. A., Terrasa, J., Muñoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J. L., Sanchez, J. J., Molina, M. A., Taron, M., Paz-Ares, L., and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. (2012). Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial. Lancet Oncol. 13, 239-246.
65. Rudolf, E., and Cervinka, M. (2003). Topoisomerases and tubulin inhibitors: a promising combination for cancer treatment. Curr. Med. Chem. Anticancer Agents 3, 421-429.
66. Sebens, S., and Schäfer, H. (2011). The tumor stroma as mediator of drug resistance - a potential target to improve cancer therapy? Curr. Pharm. Biotechnol. [Epub ahead of print]
67. Semenza, G. L. (2010). Defining the role of hypoxiainducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634.
68. Semenza, G. L. (2012). Hypoxiainducible factors in physiology and medicine. Cell 2012 148, 399-408.
69. Specenier, P., and Vermorken, J. B. (2010). Advances in the systemic treatment of head and neck cancers. Curr. Opin. Oncol. 22, 200-205.
70. Su, H. H., Chu, S. T., Hou, Y. Y., Chang, K. P., and Chen, C. J. (2006). Spindle cell carcinoma of the oral cavity and oropharynx: factors affecting outcome. J. Chin. Med. Assoc. 69, 478-483.
71. Thiery, J. P. (2002). Epithelialmesenchymal transitions in tumor progression. Nat. Rev. Cancer 2, 442-454.
72. Tommasi, S., Pinto, R., Pilato, B., and Paradiso, A. (2007). Molecular pathways and related target therapies in liver carcinoma. Curr. Pharm. Des. 13, 3279-3287.
73. Trédan, O., Galmarini, C. M., Patel, K., and Tannock,I.F.(2007). Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99, 1441-1454.
74. Troiani, T., Martinelli, E., Capasso, A., Morgillo, F., Orditura, M., De Vita, F., and Ciardiello, F. (2012). Targeting EGFR in Pancreatic Cancer Treatment. Curr. Drug Targets 13, 802-810.
75. Vander Heiden, M. G. (2011). Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10, 671-684.
76. Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., van den Weyngaert, D., Awada, A., Cupissol, D., Kienzer, H. R., Rey, A., Desaunois, I., Bernier, J., and Lefebvre, J. L. (2007). Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med. 357, 1695-1704.
77. Weber, R. G., Scheer, M., Born, I. A., Joos, S., Cobbers, J. M., Hofele, C., Reifenberger, G., Zöller, J. E., and Lichter, P. (1998). Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization.Am. J. Pathol. 153, 295-303.
78. Wong, K. K., Engelman,J. A., and Cantley, L. C. (2010). Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20, 87-90.
79. Woolgar, J. A., Rogers, S., West, C. R., Errington, R. D., Brown, J. S., and Vaughan, E. D. (1999). Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol. 35, 257-265.
80. Zeisberg, M., and Neilson, E. G. (2009). Biomarkers for epithelialmesenchymal transitions. J. Clin. Invest. 119, 1429-1437.